FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134813321> ?p ?o ?g. }

• W3134813321 abstract "Abstract Background Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imaging agents for positron emission tomography and image-guided surgery. However, some of these antibodies have safety concerns such as infusion reactions, limiting their use in imaging applications. Nimotuzumab is a therapeutic monoclonal antibody that is specific for EGFR and has been used as a therapy in a number of countries. Methods Formulation of IRDye800CW-nimotuzumab for a clinical trial application was prepared. The physical, chemical, and pharmaceutical properties were tested to develop the specifications to determine stability of the product. The acute and delayed toxicities were tested and IRDye800CW-nimotuzumab was determined to be non-toxic. Non-compartmental pharmacokinetics analysis was used to determine the half-life of IRDye800CW-nimotuzumab. Results IRDye800CW-nimotuzumab was determined to be non-toxic from the acute and delayed toxicity study. The half-life of IRDye800CW-nimotuzumab was determined to be 38 ± 1.5 h. A bi-exponential analysis was also used which gave a t 1/2 alpha of 1.5 h and t 1/2 beta of 40.8 h. Conclusions Here, we show preclinical studies demonstrating that nimotuzumab conjugated to IRDye800CW is safe and does not exhibit toxicities commonly associated with EGFR targeting antibodies." @default.
• W3134813321 created "2021-03-15" @default.
• W3134813321 creator A5012409078 @default.
• W3134813321 creator A5021700676 @default.
• W3134813321 creator A5032549592 @default.
• W3134813321 creator A5034431480 @default.
• W3134813321 creator A5074593945 @default.
• W3134813321 creator A5076963479 @default.
• W3134813321 creator A5077077456 @default.
• W3134813321 creator A5078704965 @default.
• W3134813321 creator A5078805938 @default.
• W3134813321 creator A5079203897 @default.
• W3134813321 date "2021-03-12" @default.
• W3134813321 modified "2023-09-25" @default.
• W3134813321 title "Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety" @default.
• W3134813321 cites W1964321121 @default.
• W3134813321 cites W1982104166 @default.
• W3134813321 cites W1997168106 @default.
• W3134813321 cites W2028009636 @default.
• W3134813321 cites W2028946041 @default.
• W3134813321 cites W2031019426 @default.
• W3134813321 cites W2077857302 @default.
• W3134813321 cites W2105638105 @default.
• W3134813321 cites W2106235642 @default.
• W3134813321 cites W2324918849 @default.
• W3134813321 cites W2519930924 @default.
• W3134813321 cites W2554295594 @default.
• W3134813321 cites W2563665409 @default.
• W3134813321 cites W2608695549 @default.
• W3134813321 cites W2780183249 @default.
• W3134813321 cites W2780483150 @default.
• W3134813321 cites W2788340667 @default.
• W3134813321 cites W2791002029 @default.
• W3134813321 cites W2795715780 @default.
• W3134813321 cites W2802371551 @default.
• W3134813321 cites W2802536159 @default.
• W3134813321 cites W2810142842 @default.
• W3134813321 doi "https://doi.org/10.1186/s12885-021-08003-3" @default.
• W3134813321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7953729" @default.
• W3134813321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33711962" @default.
• W3134813321 hasPublicationYear "2021" @default.
• W3134813321 type Work @default.
• W3134813321 sameAs 3134813321 @default.
• W3134813321 citedByCount "8" @default.
• W3134813321 countsByYear W31348133212021 @default.
• W3134813321 countsByYear W31348133212022 @default.
• W3134813321 countsByYear W31348133212023 @default.
• W3134813321 crossrefType "journal-article" @default.
• W3134813321 hasAuthorship W3134813321A5012409078 @default.
• W3134813321 hasAuthorship W3134813321A5021700676 @default.
• W3134813321 hasAuthorship W3134813321A5032549592 @default.
• W3134813321 hasAuthorship W3134813321A5034431480 @default.
• W3134813321 hasAuthorship W3134813321A5074593945 @default.
• W3134813321 hasAuthorship W3134813321A5076963479 @default.
• W3134813321 hasAuthorship W3134813321A5077077456 @default.
• W3134813321 hasAuthorship W3134813321A5078704965 @default.
• W3134813321 hasAuthorship W3134813321A5078805938 @default.
• W3134813321 hasAuthorship W3134813321A5079203897 @default.
• W3134813321 hasBestOaLocation W31348133211 @default.
• W3134813321 hasConcept C112705442 @default.
• W3134813321 hasConcept C121608353 @default.
• W3134813321 hasConcept C126322002 @default.
• W3134813321 hasConcept C143998085 @default.
• W3134813321 hasConcept C159654299 @default.
• W3134813321 hasConcept C203014093 @default.
• W3134813321 hasConcept C2776055544 @default.
• W3134813321 hasConcept C2779438470 @default.
• W3134813321 hasConcept C29730261 @default.
• W3134813321 hasConcept C542903549 @default.
• W3134813321 hasConcept C71924100 @default.
• W3134813321 hasConcept C98274493 @default.
• W3134813321 hasConceptScore W3134813321C112705442 @default.
• W3134813321 hasConceptScore W3134813321C121608353 @default.
• W3134813321 hasConceptScore W3134813321C126322002 @default.
• W3134813321 hasConceptScore W3134813321C143998085 @default.
• W3134813321 hasConceptScore W3134813321C159654299 @default.
• W3134813321 hasConceptScore W3134813321C203014093 @default.
• W3134813321 hasConceptScore W3134813321C2776055544 @default.
• W3134813321 hasConceptScore W3134813321C2779438470 @default.
• W3134813321 hasConceptScore W3134813321C29730261 @default.
• W3134813321 hasConceptScore W3134813321C542903549 @default.
• W3134813321 hasConceptScore W3134813321C71924100 @default.
• W3134813321 hasConceptScore W3134813321C98274493 @default.
• W3134813321 hasFunder F4320334600 @default.
• W3134813321 hasIssue "1" @default.
• W3134813321 hasLocation W31348133211 @default.
• W3134813321 hasLocation W31348133212 @default.
• W3134813321 hasLocation W31348133213 @default.
• W3134813321 hasOpenAccess W3134813321 @default.
• W3134813321 hasPrimaryLocation W31348133211 @default.
• W3134813321 hasRelatedWork W1995586676 @default.
• W3134813321 hasRelatedWork W2010317470 @default.
• W3134813321 hasRelatedWork W2056061156 @default.
• W3134813321 hasRelatedWork W2056231397 @default.
• W3134813321 hasRelatedWork W2323576217 @default.
• W3134813321 hasRelatedWork W2410968903 @default.
• W3134813321 hasRelatedWork W2774225352 @default.
• W3134813321 hasRelatedWork W3080441546 @default.
• W3134813321 hasRelatedWork W3148165406 @default.
• W3134813321 hasRelatedWork W4214585610 @default.

• next